

## Active substances set

**Search phrase:** trifluridine / tipiracil hydrochloride

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Malignant stomach cancer

**Trifluridine /  
tipiracil  
hydrochloride**

Trifluridine / Tipiracil Hydrochloride is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

 **NO REIMBURSEMENT**  
 **ESMO**

### Colon and rectum cancer

**Trifluridine /  
tipiracil  
hydrochloride**

Trifluridine / Tipiracil Hydrochloride is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. Trifluridine / Tipiracil Hydrochloride is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

 **FULL REIMBURSEMENT**  
 **ESMO**